Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-119758
Filing Date
2019-04-25
Accepted
2019-04-25 16:32:56
Documents
12
Effectiveness Date
2019-04-25

Document Format Files

Seq Description Document Type Size
1 DEFA14A d692518ddefa14a.htm DEFA14A 31563
2 GRAPHIC g692518s1aa.jpg GRAPHIC 54668
3 GRAPHIC g692518s1bb.jpg GRAPHIC 28154
4 GRAPHIC g692518s1c.jpg GRAPHIC 5856
5 GRAPHIC g692518s1d.jpg GRAPHIC 1996
6 GRAPHIC g692518s1ee.jpg GRAPHIC 22143
7 GRAPHIC g692518s1f.jpg GRAPHIC 17555
8 GRAPHIC g692518s1g.jpg GRAPHIC 2641
9 GRAPHIC g692518s1h.jpg GRAPHIC 2086
10 GRAPHIC g692518s1i.jpg GRAPHIC 1339
11 GRAPHIC g692518s2a.jpg GRAPHIC 17554
12 GRAPHIC g692518s2b.jpg GRAPHIC 2201
  Complete submission text file 0001193125-19-119758.txt   249376
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-30171 | Film No.: 19767895
SIC: 2836 Biological Products, (No Diagnostic Substances)